Solubility and Bioavailability: Who will you meet?

  • stegemann Dr. Sven Stegemann
    Director Global Pharmaceutical Business Development, Capsugel NV
    Pfizer, Germany
  • Elder Dr. David Elder
    Director PreClinical Development
    GlaxoSmithKline, UK
  • Moeschwitzer Dr. Jan Möschwitzer
    Head Early Pharmaceutical Development
    Solvay Pharmaceuticals B.V., The Netherlands
  • DR-Ron Dr. Ron Liu
    President and Chief Executive Officer
    AustarPharma, USA

Predicting and overcoming poor solubility with new technologies and methods

Solubility and Bioavailability - Overview

After the successful Solubility and Bioavailability Conference cycle in 2008 and 2009, IQPC today proudly informs you about the upcoming 3rd annual international Solubility and Bioavailability Conference 2010.

As you are all aware of, modern lead optimisation requires not only the establishment of a structure-activity relationship, but also of structure-property relationships. Solubility as one of the main parameters can thereby be addressed by different methods and technologies. Many companies are still struggling with new techniques to measure, predict and improve solubility.

Don’t miss our International Conference and:

  • Understand how to select leads with good solubility potential to enhance hit-to-lead
  • Compare liquid, nanoparticles, co-crystals and amorphous concepts to ensure bioavailability
  • Find new options for improving bioavailability of poorly soluble drugs, e.g. new dosage forms, new solvents, amorphous compounds or co-crystals

Testimonials:

A very useful ground for sharing experiences with others working in the field of pharmaceutical formulation development.
Dorotha Kiss, Formulation Scientist, Oedeon Richter PLC
Good and great overview about enhancing drug delivery aspects.
Carsten Timpe, Ph.D., Fellow, Novartis Pharma
Sponsors Media Partners
Sponsors MediaPartners

[ Register Now ]